GET DAILY SIGNALSWhy Is Replimune Group (REPL) Stock Up +7.04% Today?
Key Takeaways
- REPL shares climbed roughly +7.04% to about $18.85, extending a powerful multi-week rally and setting a new 52-week high.
- The move extends momentum from last week's post-earnings surge, after the company reported a narrower fiscal Q2 net loss and early traction for its newly launched melanoma therapy, TUDRIQEV.
- Fresh analyst price-target hikes — Leerink Partners to $31 and Jefferies to $29 — provided an additional tailwind.
- Elevated short interest (roughly 34% of the free float) is amplifying the upward move as bearish positions are squeezed.
- The stock is trading above its 50-day and 200-day moving averages, with momentum indicators in overbought territory.
- For more detail on valuation, results, and outlook, explore Replimune's Price Targets, Earnings, and Forecast pages.
- To see how AI-powered strategies are positioned across thousands of tickers, explore Trending AI Robots.
Opening Summary
Replimune Group, Inc. (REPL) is a Woburn, Massachusetts-based biotechnology company that develops oncolytic immunotherapies built on its proprietary RPx platform. Its lead product, RP1 (vusolimogene oderparepvec) — marketed as TUDRIQEV — received FDA accelerated approval in August 2026 for adults with advanced cutaneous melanoma whose disease has progressed after anti-PD-1 therapy, used in combination with Bristol Myers Squibb's Opdivo (nivolumab).
In Monday's session, shares of REPL advanced about +7.04%, rising roughly $1.24 to near $18.85 from a prior close of $17.61. The gain extends a breakout that has carried the stock well above its prior 52-week high, as investors continue to reward the company's transition from a clinical-stage developer into a commercial enterprise.
Post-Earnings Momentum and a Narrower Quarterly Loss
The primary driver of the recent strength traces back to last week's fiscal second-quarter results. Replimune reported a net loss of about $57.1 million, down from $83.1 million a year earlier, while its adjusted loss of $0.54 per share came in well ahead of consensus estimates near a $0.75 loss. Although the quarter predated the start of commercial TUDRIQEV shipments, the improving cost trajectory and a cash position of roughly $307.8 million reinforced confidence in the company's runway and launch execution.
Early TUDRIQEV Launch Traction
Beyond the headline numbers, markets have latched onto early commercial signals. Management disclosed that more than 15 institutions had already written TUDRIQEV prescriptions within the first few weeks of launch, with roughly 20 accounts placing the therapy on formulary and proactive engagement across more than 70% of the initial 200 target accounts. With an estimated 10,000 addressable U.S. patients annually and a list price of approximately $450,000 per treatment course, the launch progress is shifting the investment narrative from binary regulatory risk toward commercial execution.
Analyst Price-Target Hikes
The rally has also been reinforced by bullish analyst revisions. Leerink Partners raised its price target to $31 from $19, citing confidence in the U.S. launch, while Jefferies lifted its target to $29 from $24. These upward revisions — tied explicitly to the drug's early adoption — have given fundamental-minded investors fresh justification to bid the stock higher even after its steep climb.
Short Squeeze and Technical Breakout
Technical factors are magnifying the move. Short interest in REPL has remained elevated near 34% of the free float, and the continued advance is forcing bearish traders to cover, adding buying pressure. The stock's push through its prior 52-week high has broken key resistance, while the price sits comfortably above its 50-day and 200-day moving averages. The 14-day relative strength index has climbed into overbought territory, a sign of strong momentum that also warrants caution around potential near-term pullbacks.
Market Context and Trading Activity
The gain in REPL has been driven primarily by company-specific catalysts rather than a broad sector move, though the stock has outperformed the wider biotechnology complex over the past month. Trading activity has been elevated during the rally, and the stock's climb to new highs reflects concentrated investor conviction around the TUDRIQEV launch rather than a synchronized surge across the broader market. Unlike index-level moves, Replimune's advance is a single-name story centered on execution milestones.
What Comes Next for REPL
Looking ahead, investors will focus on the pace of TUDRIQEV adoption, including prescription trends, formulary wins, and the company's ability to convert early interest into sustained revenue. Replimune's accelerated approval remains contingent on confirmatory trials, with the Phase 3 IGNYTE-3 study now enrolling and complete overall survival data expected around 2030. The company's capital position is expected to fund operations into 2027, but ongoing losses and potential future dilution remain key risks. A lingering securities class action tied to the drug's earlier regulatory setbacks also represents a legal overhang that investors will monitor.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing AI trading bots under current market conditions. While Tickeron offers hundreds of AI-driven bots covering thousands of tickers, only top performers are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see how AI-powered strategies are navigating today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 185 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.417) is normal, around the industry mean (3.104). P/E Ratio (-6.556) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement